KIAA0240 Inhibitors
Chemical inhibitors of KIAA0240 act through various cellular mechanisms to achieve functional inhibition of the protein. Staurosporine, a potent kinase inhibitor, targets the kinases responsible for the phosphorylation of numerous proteins. In the case of KIAA0240, staurosporine can lead to reduced phosphorylation, thereby affecting the protein's activation and its ability to function within the cell. Similarly, LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases (PI3K), can disrupt the PI3K/AKT pathway, a key signaling route that may be necessary for KIAA0240's activity. By impeding PI3K, these inhibitors can diminish AKT activity, indirectly leading to a functional inhibition of KIAA0240 due to altered cellular signaling.
Further down the signaling cascade, PD98059 and U0126, inhibitors of the MEK1/2 enzymes, can prevent the activation of the ERK pathway. Since ERK can regulate a variety of proteins, its inhibition can decrease the phosphorylation and activity of proteins that may interact with or regulate KIAA0240. The mTOR inhibitor rapamycin and the proteasome inhibitors bortezomib and MG132 exert their effects by disrupting cellular homeostasis, which can indirectly impact KIAA0240. Rapamycin binds to FKBP12 and inhibits mTOR, a central controller of cell growth, leading to a reduction in protein synthesis that could affect KIAA0240 function. Bortezomib and MG132 cause the accumulation of misfolded or damaged proteins, which can place stress on the regulatory pathways involving KIAA0240, resulting in its functional inhibition. Additionally, inhibitors like SB203580, SP600125, ZM-447439, and Alsterpaullone target other kinases and proteins involved in cell cycle control and transcriptional regulation. SB203580 and SP600125, which inhibit p38 MAP kinase and JNK respectively, alter the activity of transcription factors and cytokine profiles that are crucial for KIAA0240's regulatory functions. ZM-447439 disrupts cell division by inhibiting Aurora kinases, potentially affecting KIAA0240's role in mitotic processes, while Alsterpaullone's inhibition of cyclin-dependent kinases can modify cell cycle progression and thus KIAA0240's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, known to affect multiple signaling pathways. It can indirectly inhibit KIAA0240 by targeting the kinases that regulate its phosphorylation state, thereby affecting its activation state and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of PI3K, a kinase involved in the AKT signaling pathway. By inhibiting PI3K, LY294002 can reduce AKT activity, which may be necessary for the proper function or localization of KIAA0240, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is upstream of the ERK pathway. As ERK activity can regulate a range of proteins, inhibition by PD98059 can decrease the phosphorylation and activity of proteins that interact with or regulate KIAA0240. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a central regulator of cell growth and metabolism. mTOR inhibition can lead to decreased protein synthesis and indirectly affect the function of KIAA0240 by altering cellular homeostasis and signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase can lead to altered transcription factor activity and cytokine production, which could disrupt signaling pathways that regulate KIAA0240 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAP kinase pathway. Inhibition of JNK signaling can affect transcription factors and other proteins that are crucial for the regulation and function of KIAA0240. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAP kinase pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK, which could be a regulator of proteins that modulate KIAA0240 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can prevent the phosphorylation and activation of AKT. Through PI3K inhibition, wortmannin can indirectly affect KIAA0240 by disrupting the signaling pathways that control its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded or damaged proteins. This accumulation can stress cellular pathways that may involve KIAA0240, indirectly leading to its inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is an inhibitor of the ubiquitin-proteasome pathway. By preventing the degradation of ubiquitinated proteins, MG132 can affect cellular signaling and regulatory pathways that include KIAA0240, leading to its functional inhibition. | ||||||